SB 773812

Drug Profile

SB 773812

Alternative Names: 773812; GW 773812

Latest Information Update: 18 Jun 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antipsychotics
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 18 Jun 2015 No recent reports on development identified - Phase-I for Schizophrenia in Spain and United Kingdom (PO)
  • 18 Jun 2015 No recent reports on development identified - Phase-II for Schizophrenia in USA, Belgium, Costa Rica, Czech Republic, India, Peru and Russia (PO)
  • 18 Mar 2011 Pharmacokinetics data from a phase I trial in Schizophrenia released by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top